XTX Topco Ltd Takes $1.69 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

XTX Topco Ltd acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,333 shares of the biotechnology company's stock, valued at approximately $1,692,000.

Other large investors have also recently bought and sold shares of the company. Westfield Capital Management Co. LP lifted its stake in shares of Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after purchasing an additional 170,942 shares during the period. Avoro Capital Advisors LLC increased its position in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock valued at $572,341,000 after buying an additional 229,995 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock valued at $625,075,000 after buying an additional 267,881 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock valued at $278,760,000 after buying an additional 155,971 shares in the last quarter. Finally, Fred Alger Management LLC increased its position in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock valued at $41,879,000 after buying an additional 120,952 shares in the last quarter.

Ascendis Pharma A/S Trading Up 0.7 %

ASND traded up $0.93 during midday trading on Friday, reaching $133.00. The company's stock had a trading volume of 334,483 shares, compared to its average volume of 512,758. The firm has a market capitalization of $8.07 billion, a price-to-earnings ratio of -16.46 and a beta of 0.67. Ascendis Pharma A/S has a 1 year low of $101.43 and a 1 year high of $161.00. The stock's 50-day moving average is $130.53 and its 200-day moving average is $132.66.

Analysts Set New Price Targets

ASND has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Oppenheimer lowered their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. Wedbush reaffirmed an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen decreased their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating on the stock in a research report on Friday, November 15th. Finally, Bank of America upped their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.